TL;DR
This study reveals that knocking out miR-150 in mice significantly reduces atherosclerosis by dampening the inflammatory response, primarily within macrophages. This protective effect is linked to the upregulation of PDLIM1, a protein that helps stabilize atherosclerotic plaques.
What Problem Does This Paper Address?
Atherosclerosis, a chronic inflammatory disease, is a leading cause of cardiovascular events. While microRNAs (miRNAs) are known to regulate inflammatory responses, the specific role of miR-150 in atherosclerosis has remained unclear. This paper aims to elucidate miR-150's contribution to atherosclerosis development and explore its potential as a therapeutic target.
Methods
The researchers employed a multi-pronged approach:
- Genetic Models: They utilized double-knockout mice lacking both miR-150 and ApoE (a gene crucial for lipid metabolism and atherosclerosis development) and compared them to ApoE-deficient mice.
- Bone Marrow Transplantation: To pinpoint the cellular source of miR-150's effects, they transplanted bone marrow from miR-150/ApoE double knockouts into ApoE-deficient recipients.
- Histological Analysis: Standard techniques like H&E staining, picrosirius red for collagen, and Oil Red O for lipid accumulation were used to assess plaque morphology and composition.
- Molecular Biology Techniques: Quantitative PCR (qPCR) was used to measure mRNA expression of inflammatory cytokines and PDLIM1. Western blotting was employed to assess protein levels, particularly phosphorylated p65 (a key component of the NF-κB inflammatory pathway).
- In Vitro Studies: Bone marrow-derived macrophages (BMDMs) were cultured and stimulated with oxidized LDL (Ox-LDL) to investigate cellular responses. siRNA-mediated knockdown was used to study the role of PDLIM1.
- Luciferase Reporter Assays: These were used to confirm the direct binding of miR-150 to the 3'UTR of PDLIM1 mRNA.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- miR-150 as a Pro-Atherosclerotic Factor: Contrary to some previous findings in other contexts, this study strongly implicates miR-150 as a driver of atherosclerosis, particularly by promoting inflammation.
- Macrophage-Centric Action: The research highlights that miR-150's atheroprotective effects are largely mediated through its actions within macrophages, rather than other cell types like endothelial cells or smooth muscle cells.
- PDLIM1 as a Key Downstream Target: The identification of PDLIM1 as a direct target of miR-150 is a significant finding. Upregulation of PDLIM1 in the absence of miR-150 appears to be the mechanism by which inflammation is suppressed and plaque stability is enhanced.
- Plaque Stabilization Mechanism: miR-150 deficiency not only reduces lesion size but also improves plaque stability by increasing collagen and smooth muscle cell content while decreasing macrophage infiltration and lipid accumulation.
Key Results
- Reduced Lesion Size: Double-knockout mice (miR-150<sup>-/-</sup>ApoE<sup>-/-</sup>) exhibited significantly smaller atherosclerotic lesions in the aorta compared to ApoE<sup>-/-</sup> mice after 28 weeks on a high-fat diet (21.31% vs. 38.21%).
- Attenuated Inflammatory Response: mRNA and serum levels of key pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, iNOS, MCP-1) were significantly reduced in miR-150<sup>-/-</sup>ApoE<sup>-/-</sup> mice.
- Improved Plaque Stability: Plaque stability scores were significantly higher in miR-150<sup>-/-</sup>ApoE<sup>-/-</sup> mice, characterized by increased collagen and smooth muscle cell content, and decreased macrophage infiltration and lipid accumulation.
- PDLIM1 Upregulation: PDLIM1 expression was significantly upregulated in BMDMs from miR-150<sup>-/-</sup>ApoE<sup>-/-</sup> mice.
- NF-κB Pathway Inhibition: Phosphorylated p65 (a key NF-κB signaling component) and phosphorylated IκBα were reduced in BMDMs from miR-150<sup>-/-</sup>ApoE<sup>-/-</sup> mice.
- Macrophage Migration Inhibition: miR-150 deficiency significantly inhibited macrophage migration in vitro.
- Reversal by PDLIM1 Knockdown: Knocking down PDLIM1 in miR-150 deficient macrophages reversed the suppression of inflammatory cytokine secretion and macrophage infiltration.
Limitations and Future Work
- In Vivo vs. In Vitro Discrepancies: While the study focused on macrophages, the authors acknowledge that miR-150 might engage distinct downstream pathways in different cell types, suggesting further investigation into these interactions.
- Broader MicroRNA Roles: The paper briefly mentions that other miRNAs are involved in plaque stability, implying that miR-150's role might be part of a larger regulatory network.
- Therapeutic Potential: The findings strongly suggest miR-150 as a promising therapeutic target for atherosclerosis management. Future work could focus on developing strategies to inhibit miR-150 activity in relevant cell types.
- Human Relevance: While human samples showed increased miR-150 in CHD patients, further studies are needed to fully translate these findings to clinical applications.
Summary updated